Search results
Added:
4 months ago
Learn about the management of HFrEF and HFpEF from Dr Michelle Kittleson (Cedars-Sinai Heart Institute, Los Angeles, US).This two-part video lecture series, part of Women As One's CLIMB® 2025 Skills Training Program, provides a comprehensive overview of key treatments and therapy approaches to cardiomyopathies.In this lecture, Dr Kittleson provides an in-depth review of the management of HFrEF…
View more
Added:
1 month ago
Master the diagnostic complexities of hypertrophic cardiomyopathy (HCM) with Dr Sara Saberi, a leading expert in inherited cardiovascular diseases.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, provides essential insights into the nuanced approach required for accurate HCM diagnosis and risk stratification.Dr Saberi…
View more
Added:
1 month ago
Navigate the rapidly evolving treatment landscape for hypertrophic cardiomyopathy with Dr Anjali Tiku Owens, a renowned expert in inherited cardiovascular diseases and advanced heart failure.This comprehensive presentation, part of the Cardiomyopathies track of Women As One's CLIMB® 2025 Skills Training Program, explores both established and emerging therapeutic approaches for obstructive and non…
View more
Added:
4 months ago
Discover different imaging options for the diagnosis of cardiomyopathies from Dr Gabriella Captur (Royal Free London NHS Foundation Trust, London, UK).This two-part video lecture series, part of Women As One's CLIMB® 2025 Skills Training Program, provides a comprehensive overview of key treatments and therapy approaches to cardiomyopathies.Dr Captur explores cardiac imaging techniques for the…
View more
Added:
1 year ago
AHA 23 - We are joined by Dr Demilade Adedinsewo (Mayo Clinic, US) to discuss the findings from a study investigating the effectiveness of an artificial intelligence-enabled ECG (AI-ECG) for cardiomyopathy detection in an obstetric population.In the intervention arm, the digital stethoscope correctly identified 92% of those with ejection fraction <50% and 100% of those with ejection fraction …
View more
Added:
11 months ago
AHA Conference 2024 - Safety and efficacy outcomes of nexiguran ziclumeran (NTLA-2001) in patients with transthyretin amyloidosis with cardiomyopathy (ATTR-CM).Dr Marianna Fontana (University College London, London, UK) joins us onsite at AHA Conference to discuss the findings from the nexiguran ziclumeran for ATTR-CM trial (NCT04601051).Dr Fontana discusses a phase 1, ongoing, open-label, single…
View more
Added:
6 months ago
ESC HF 25 - A study investigating CRISPR gene editing with nexiguran ziclumeran in ATTR cardiomyopathy demonstrated favourable safety and tolerability, with consistent reductions in serum TTR in both wild-type and variant disease.Prof Marianna Fontana (University College London, UK) joins us to discuss the key findings from a two-part, open-label, phase 1 study investigating the treatment effect,…
View more
Added:
1 month ago
HFSA 2025 - Post hoc analysis of ATTRibute-CM reveals significant reduction in cardiovascular mortality and death after 30 months of acoramidis in patients with ATTR-CM.Dr Ahmad Masri (Oregon Health & Science University, US) joins us to discuss a post hoc exploratory analysis from the ATTRibute-CM trial examining the timing and magnitude of cardiovascular outcome reductions with acoramidis in…
View more
Added:
2 years ago
Prof Marianna Fontana (University College London, UK) joined us to discuss the discovery and impact of antibody-associated reversal of ATTR amyloidosis–related cardiomyopathy in three patients.
Prof Fontana and her team, in a correspondence published in The New England Journal of Medicine, revealed the identification of an antibody linked to the spontaneous reversal of cardiac transthyretin…
View more
Added:
2 years ago
ESC 2023 — Prof Julian Gillmore (University College London, UK) joins us onsite to discuss the findings of the ATTRibute-CM Study (NCT03860935).
ATTRibute-CM was a randomised double-blind trial which aimed to evaluate the safety and efficacy of acoramidis in a cohort of patients diagnosed with transtherytin amyloid cardiomyopathy (ATTR-CM). 632 patients were enrolled in the trial, and were…
View more